What Will Happen to Alimera Sciences, Inc. (ALIM) Next? The Stock Just Reaches 52-Week Low

May 17, 2018 - By Robert Crowder

Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Investors sentiment decreased to 1 in 2017 Q4. Its down 0.64, from 1.64 in 2017Q3. It fall, as 4 investors sold Alimera Sciences, Inc. shares while 8 reduced holdings. 3 funds opened positions while 9 raised stakes. 28.68 million shares or 0.99% more from 28.40 million shares in 2017Q3 were reported.
Shufro Rose Ltd Co owns 10,000 shares. Morgan Stanley holds 0% or 400 shares. Blackrock has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 210,886 shares. Royal National Bank & Trust Of Canada reported 134 shares stake. Livingston Gp Asset Management Company (Operating As Southport Capital Management) owns 31,500 shares. Palo Alto Invsts Limited reported 0.17% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Strs Ohio has 43,569 shares. Virtu Limited reported 34,916 shares. Knott David M holds 0.11% or 203,000 shares in its portfolio. Jw Asset Limited Liability accumulated 966,000 shares or 1.37% of the stock. Citadel Advsr Ltd Liability Co holds 0% or 54,299 shares in its portfolio. 250,000 were reported by Orbimed Advsr Limited. Weiss Multi holds 0% in Alimera Sciences, Inc. (NASDAQ:ALIM) or 80,000 shares. Renaissance Tech Ltd Liability Co accumulated 416,400 shares or 0% of the stock. Susquehanna Group Inc Llp holds 26,098 shares.

Since January 16, 2018, it had 2 insider purchases, and 10 selling transactions for $280,303 activity. Ashman Philip sold $31,475 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) on Tuesday, January 16. The insider Green Kenneth sold $14,181. Another trade for 25,500 shares valued at $30,552 was made by Holland David on Thursday, January 18. On Thursday, January 18 Myers C. Daniel sold $63,379 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) or 52,900 shares. ARMISTICE CAPITAL – LLC bought $22,800 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) on Friday, February 2.

The stock of Alimera Sciences, Inc. (NASDAQ:ALIM) hit a new 52-week low and has $0.74 target or 5.00 % below today’s $0.78 share price. The 6 months bearish chart indicates high risk for the $54.71 million company. The 1-year low was reported on May, 17 by Barchart.com. If the $0.74 price target is reached, the company will be worth $2.74M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 0.50% or $0.0039 during the last trading session, reaching $0.7811. About 396,235 shares traded or 138.14% up from the average. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 28.28% since May 17, 2017 and is downtrending. It has underperformed by 39.83% the S&P500.

Another recent and important Alimera Sciences, Inc. (NASDAQ:ALIM) news was published by Seekingalpha.com which published an article titled: “Alimera Sciences’ (ALIM) CEO Dan Myers on Q1 2018 Results – Earnings Call Transcript” on May 06, 2018.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $54.71 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: